首頁 > 市場調查報告書 > 製藥

癌症

多發性骨髓瘤市場規模、佔有率和成長分析（按藥物類別、治療方法、通路和地區分類）－2026-2033年產業預測

市場調查報告書

商品編碼

1899391

多發性骨髓瘤市場規模、佔有率和成長分析（按藥物類別、治療方法、通路和地區分類）－2026-2033年產業預測

Multiple Myeloma Market Size, Share, and Growth Analysis, By Drug Class (Proteasome Inhibitors, Immunomodulatory Drugs), By Therapy (Immunotherapy, Chemotherapy), By Distribution channel, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月23日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，多發性骨髓瘤市場規模將達到 291.2 億美元，到 2025 年將成長至 335.2 億美元，到 2033 年將成長至 1032.5 億美元，在預測期（2026-2033 年）內複合年成長率為 15.1%。

多發性骨髓瘤發生率的上升以及腫瘤研究投入的增加預計將推動市場成長。癌症治療領域的創新，特別是CAR-T細胞療法、單株抗體和免疫查核點抑制劑的日益普及，將使業內相關人員受益。對治療方法和診斷研發的大量投入，以及對個人化醫療日益成長的關注，將為該領域的公司帶來新的機會。加強提高大眾對多發性骨髓瘤的認知度並促進早期診斷，將進一步擴大醫療服務提供者的市場。然而，高昂的治療費用、潛在的副作用、認知不足以及抗藥性的出現等挑戰可能會限制市場的長期前景。

全球多發性骨髓瘤市場按藥物類別、治療方法、通路和地區進行細分。依藥物類別分類，市場分為蛋白酶體抑制劑、免疫調節藥物、單株抗體和類固醇。依治療方法分類，市場分為免疫療法、化療、放射線治療和幹細胞移植。依通路分類，市場分為醫院、零售藥局和線上藥局。按地區分類，市場分為北美、歐洲、亞太、中東和非洲以及拉丁美洲。

多發性骨髓瘤市場成長要素

全球人口老化預計將顯著增加對多發性骨髓瘤治療的需求，並成為市場發展的關鍵促進因素。研究表明，老年人罹患多發性骨髓瘤的風險更高，這正在影響市場的擴張。隨著該疾病盛行率老齡化成長而增加，對有效治療方法和管理方案的需求預計將推動市場成長。這種人口結構變化表明，迫切需要改進治療方法和資源，以應對老年人中多發性骨髓瘤面臨的獨特挑戰。

多發性骨髓瘤市場限制因素

多發性骨髓瘤的治療方法主要集中於化療、免疫療法和幹細胞移植，但這些治療方法都伴隨著顯著的副作用，包括神經病變、感染疾病和胃腸道併發症。這些嚴重的副作用可能會使患者放棄治療，進而抑制多發性骨髓瘤治療方法市場的需求。潛在患者在權衡治療獲益與潛在的嚴重副作用時，會降低現有治療方法的整體接受度，這對多發性骨髓瘤治療的發展構成重大挑戰。這一限制凸顯了該領域對更安全、耐受性更好的治療方案的迫切需求。

多發性骨髓瘤市場趨勢

多發性骨髓瘤市場正加速向精準醫療轉型，反映出患者對個人化治療方案的認知和需求日益增強。這一趨勢使醫療服務提供者能夠根據個別基因譜和生物標記分析客製化治療方法，從而顯著提高療效並最大限度地減少副作用。透過採用精準醫療方法，企業可以改善患者的治療效果和生活品質，從而提升消費者忠誠度和偏好度。隨著對標靶治療的關注度不斷提高，多發性骨髓瘤領域的相關人員已做好充分準備，在競爭激烈的市場環境中創新並打造差異化的價值主張，以滿足患者不斷變化的需求。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲（MEA）
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭格局

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市集活動
主要企業市佔率（2025 年）

主要企業簡介

Bristol-Myers Squibb Company（US）
Amgen Inc.（US）
Johnson & Johnson（Janssen Pharmaceuticals）（US）
Novartis AG（Switzerland）
Sanofi（France）
Takeda Pharmaceutical Company Limited（Japan）
Pfizer Inc.（US）
Celgene Corporation（Bristol-Myers Squibb Company）（US）
AbbVie Inc.（US）
Genentech, Inc.（F. Hoffmann-La Roche Ltd）（US）
Karyopharm Therapeutics（US）
Teva Pharmaceutical Industries Ltd.（Israel）
ONO Pharmaceutical Co., Ltd.（Japan）
Merck & Co., Inc.（US）
Eli Lilly and Company（US）
GlaxoSmithKline plc（UK）
Bayer AG（Germany）
Takeda Oncology（Millennium Pharmaceuticals）（Japan）
Oncopeptides AB（Sweden）
Bluebird Bio, Inc.（US）

簡介目錄

Product Code: SQMIG35I2293

Multiple Myeloma Market size was valued at USD 29.12 Billion in 2024 and is poised to grow from USD 33.52 Billion in 2025 to USD 103.25 Billion by 2033, growing at a CAGR of 15.1% during the forecast period (2026-2033).

The increasing prevalence of multiple myeloma and heightened investment in oncology research are set to drive market growth. Innovations in cancer therapies, particularly the rising adoption of CAR-T cell therapy, monoclonal antibodies, and immune checkpoint inhibitors, will benefit industry players. Significant investments in the research and development of treatments and diagnostics, along with the escalating emphasis on personalized medicine, present new opportunities for companies in this sector. Increased initiatives to raise awareness of multiple myeloma and efforts to promote early diagnosis will further expand the market for providers. However, high treatment costs, the potential for adverse effects, lack of awareness, and the emergence of treatment resistance pose challenges that may restrict the positive market outlook over the long term.

Top-down and bottom-up approaches were used to estimate and validate the size of the Multiple Myeloma market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Multiple Myeloma Market Segments Analysis

Global Multiple Myeloma Market is segmented on the drug class, therapy, distribution channel, and region. By drug class, market is segmented into Proteasome Inhibitors, Immunomodulatory Drugs,Monoclonal Antibodies, and Steroids. By therapy, market is segmented into immunotherapy, chemotherapy, radiation therapy, and stem cell transplant. By distribution channel, market is segmented into hospital, retail, and online pharmacies. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Driver of the Multiple Myeloma Market

The growing global population of older individuals is poised to significantly elevate the demand for multiple myeloma treatments, acting as a crucial driver for the market. Research indicates that aging adults are at a higher risk of developing multiple myeloma, consequently influencing the expansion of the market. As the prevalence of this condition rises with age, the need for effective therapies and management solutions is expected to increase, thereby propelling market growth. This demographic shift underscores the urgency for advancements in treatments and resources dedicated to addressing the unique challenges presented by multiple myeloma in older populations.

Restraints in the Multiple Myeloma Market

The treatment landscape for multiple myeloma predominantly features chemotherapy, immunotherapy, and stem cell transplants; however, these approaches come with significant risks of adverse effects, including neuropathy, infections, and gastrointestinal complications. Such severe side effects can discourage patients from pursuing treatment options, ultimately hindering the demand for therapies within the multiple myeloma market. As potential patients weigh the benefits against the potential for debilitating repercussions, the overall acceptance of available treatment modalities may diminish, posing a substantial challenge to the growth and advancement of multiple myeloma therapies. This restraint highlights the need for safer, more tolerable treatment alternatives in this field.

Market Trends of the Multiple Myeloma Market

The market for multiple myeloma is increasingly shifting towards personalized medicine, reflecting a growing awareness and demand among patients for tailored treatment options. This trend allows healthcare providers to customize therapies based on individual genetic profiles and biomarker analysis, significantly enhancing treatment efficacy while minimizing adverse effects. By adopting a personalized medicine approach, companies can improve patient outcomes and quality of life, fostering loyalty and preference among consumers. As the emphasis on targeted therapies continues to rise, stakeholders within the multiple myeloma sector are positioned to innovate and differentiate their offerings to meet the evolving needs of patients in a competitive landscape.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree Of Competition
Top Investment Pockets
Ecosystem Of the Market
Value Chain Analysis
Raw Material Analysis
Pricing Analysis
Consumer Behaviour Analysis
PESTLE Analysis

Multiple Myeloma Market, By Drug Class

Market Overview
Proteasome Inhibitors
Immunomodulatory Drugs
Monoclonal Antibodies
Steroids

Multiple Myeloma Market, By Therapy

Market Overview
Immunotherapy
Chemotherapy
Radiation Therapy
Stem Cell Transplant

Multiple Myeloma Market, By Distribution Channel

Market Overview
Hospital
Retail
Online Pharmacies

Multiple Myeloma Market Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2025

Key Company Profiles

Bristol-Myers Squibb Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (Janssen Pharmaceuticals) (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Celgene Corporation (Bristol-Myers Squibb Company) (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genentech, Inc. (F. Hoffmann-La Roche Ltd) (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Karyopharm Therapeutics (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ONO Pharmaceutical Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Oncology (Millennium Pharmaceuticals) (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Oncopeptides AB (Sweden)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bluebird Bio, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments